Trusted Resources: Education
Scientific literature and patient education texts
Divergent Developmental Trajectories in Two Siblings With Neuropathic Mucopolysaccharidosis Type II (Hunter Syndrome) Receiving Conventional and Novel Enzyme Replacement Therapies: A Case Report
source: JIMD reports
year: 2021
authors: Tomita K,Okamoto S,Seto T,Hamazaki T,So S,Yamamoto T,Tanizawa K,Sonoda H,Sato Y
summary/abstract:Mucopolysaccharidosis type II (MPS II; Hunter syndrome) is an X-linked recessive lysosomal storage disease caused by a mutation in the gene and characterized by systemic accumulations of glycosaminoglycans. Its somatic symptoms can be relieved by enzyme replacement therapy (ERT) with idursulfase, but because the enzyme cannot cross the blood-brain-barrier (BBB), it does not address the progressive neurodegeneration and subsequent central nervous system (CNS) manifestations seen in patients with neuropathic MPS-II. However, pabinafusp alfa, a human iduronate-2-sulfatase (IDS) fused with a BBB-crossing anti-transferrin receptor antibody, has been shown to be efficacious against both the somatic and CNS symptoms of MPS II. We report two cases of MPS-II in Japanese siblings sharing the same G140V mutation in the gene, who showed markedly contrasting developmental trajectories following enzyme replacement therapy (ERT). Sibling 1 was diagnosed at 2 years of age, started undergoing conventional ERT shortly afterward, and scored a developmental quotient (DQ) of 53 on the Kyoto Scale of Psychological Development (KSPD) at 4 years of age. Sibling 2 was diagnosed prenatally and received conventional ERT from the age of 1 month through 1 year and 11 months, when he switched to pabinafusp alpha. He attained a DQ of 104 at age 3 years and 11 months, along with significant declines in heparan sulfate concentrations in the cerebrospinal fluid. This marked difference in neurocognitive development highlights the importance of early initiation of ERT with a BBB-penetrating enzyme in patients with neuropathic MPS-II.
organization: Department of Pediatrics Osaka City University Graduate School of Medicine Japan.DOI: 10.1002/jmd2.12239
read more
Related Content
-
Enzyme Replacement Therapy With Pabinafusp Alfa for Neuronopathic Mucopolysaccharidosis II: An Integrated Analysis o...Enzyme replacement therapy (ERT) improve...
-
A Review of the Clinical Outcomes in Idursulfase-Treated and Untreated Filipino Patients With Mucopolysaccharidosis ...Mucopolysaccharidosis type II (MPS II; H...
-
Drug Delivery for Neuronopathic Lysosomal Storage Diseases: Evolving Roles of the Blood Brain Barrier and Cerebrospi...Whereas significant strides have been ma...
-
Transcatheter Aortic Valve Implantation for Severe Aortic Stenosis in a Patient With Mucopolysaccharidosis Type II (...Mucopolysaccharidosis type II, known as ...
-
Clinical Utility of Elosulfase Alfa in the Treatment of Morquio A SyndromeMucopolysaccharidosis type IVA (MPS IVA ...
-
The Impact of Excluding Nonrandomized Studies From Systematic Reviews in Rare Diseases: “The Example of Meta-A...Nonrandomized studies are usually exclud...
-
AVROBIO Receives Rare Pediatric Disease Designation from the U.S. FDA for AVR-RD-05, a Gene Therapy for Mucopolysacc...AVROBIO, Inc., a leading clinical-stage ...